Last reviewed · How we verify
Recombinant Human Plasma Gelsolin — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Recombinant Human Plasma Gelsolin (Recombinant Human Plasma Gelsolin) — BioAegis Therapeutics Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Recombinant Human Plasma Gelsolin TARGET | Recombinant Human Plasma Gelsolin | BioAegis Therapeutics Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Recombinant Human Plasma Gelsolin CI watch — RSS
- Recombinant Human Plasma Gelsolin CI watch — Atom
- Recombinant Human Plasma Gelsolin CI watch — JSON
- Recombinant Human Plasma Gelsolin alone — RSS
Cite this brief
Drug Landscape (2026). Recombinant Human Plasma Gelsolin — Competitive Intelligence Brief. https://druglandscape.com/ci/recombinant-human-plasma-gelsolin. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab